Taken together, our results demonstrated that inhibiting Meox1/Cthrc1/p-Smad2/3 signaling suppressed CFs-to-Myofbs conversion and prevented fibrotic remodeling and heart failure, which may provide clinical translational implications for improving the prognosis of MI patients. Here, SMAD2 is linked to heart failure.